ACA
DNTH icon

Anchor Capital Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Anchor Capital Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,344
Closed -$1.03M – 251
2018
Q4 		$1.03M Buy
+11,344
New +$1.55M 0.04% 168

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Anchor Capital Advisors's DNTH Position: Q1 2019 in Review

Anchor Capital Advisors sold out of Dianthus Therapeutics (DNTH) in Q1 2019, closing a stake of 11,344 shares — an estimated $1.03M sold.

Anchor Capital Advisors first reported a position in DNTH in Q4 2018 and held it in 1 quarter. The position peaked at $1.03M in Q4 2018. 63 funds tracked by Wall St. Rank hold DNTH as of Q1 2019.

  • Anchor Capital Advisors reported no remaining Dianthus Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Anchor Capital Advisors sold 11,344 Dianthus Therapeutics shares in Q1 2019, an estimated $1.03M.
  • Anchor Capital Advisors first reported a position in Dianthus Therapeutics in Q4 2018 and held it in 1 quarter.
  • Anchor Capital Advisors's Dianthus Therapeutics position peaked at $1.03M in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2019.

Based on Anchor Capital Advisors's 13F filing for Q1 2019, filed 9 May 2019.